The purpose of this protocol addendum is to provide participants from Study LOXO-NGR-21001 (J3T-OX-JZTA), who continue to receive benefit from LOXO-260, the opportunity for continued access to LOXO-260.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Jared Weiss
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Phase 1 Trials (all cancers))
25-0522
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
